X

Trial Profile

A Tolerance, Safety and Pharmacokinetic Ascending Dose Phase I Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive Malignant in Advanced Malignant Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 05 Aug 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Disitamab vedotin (Primary)
Indications Breast cancer; Cholangiocarcinoma; Gastric cancer; Solid tumours; Urogenital cancer
Focus Adverse reactions
Sponsors RemeGen

Most Recent Events

27 Feb 2020 Planned End Date changed from 1 Dec 2019 to 1 Jun 2020.
27 Feb 2020 Planned primary completion date changed from 1 Dec 2017 to 1 May 2020.
25 Jan 2020 Status changed from active, no longer recruiting to completed according to results presented at the 2020 Gastrointestinal Cancers Symposium.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com